Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
30 Results for "
mPTP Inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (30)
30 Results for "mPTP Inhibitor" in MCE Product Catalog:
877
877 Publications Verification
Target:
Research Areas:
Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
7
7 Cited Publications
Target:
Research Areas:
ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening. ER-000444793 inhibits mPTP with an IC50 of 2.8 μM.
3
3 Cited Publications
Cat. No.: HY-N0237
CAS No.: 126054-77-1
1
1 Cited Publications
Target:
Research Areas:
MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible MAO-A (IC50=37 nM) and MAO-B (IC50=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease . MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-175715
CAS No.: 3077720-24-9
Target:
Research Areas:
NRG1271 is an orally active mitochondrial permeability transition pore (mPTP) inhibitor with blood-brain barrier penetration. NRG1271 can be used for the study of Neurological Disease .
Cat. No.: HY-N0663
CAS No.: 20501-56-8
Cat. No.: HY-P6437A
Target:
Research Areas:
Cat. No.: HY-157088
Purity: 99.49%
Target:
Research Areas:
C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .
Target:
Research Areas:
GNX-865 is a mitochondrial permeability transition pore (mPTP) inhibitor that protects against ischemia-reperfusion injury in vivo .
Cat. No.: HY-P6437
CAS No.: 2770267-63-3
Target:
Research Areas:
Target:
Research Areas:
ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels .
Cat. No.: HY-172959
CAS No.: 554414-59-4
Target:
Research Areas:
mPTP-IN-1 (Compound 14e) is a mitochondrial permeability transition pore (mPTP) inhibitor. mPTP-IN-1 blocks calcium-induced mPTP opening by targeting the C subunit of ATP synthase. mPTP-IN-1 can be used to study myocardial ischemia/reperfusion injury (IRI) .
Cat. No.: HY-116550
CAS No.: 16378-22-6
Target:
Research Areas:
Piroheptine hydrochloride is an anticholinergic agent to inhibit dopamine uptake. Piroheptine hydrochloride prevents loss of striatal dopamine induced by MPTP (HY-15608). Piroheptine hydrochloride can be used for research in Parkinson .
Target:
Research Areas:
(Rac)-Rasagiline (AGN1135) is the racemate of Rasagiline. (Rac)-Rasagiline is a selective type B MAO (MAO-B) inhibitor. (Rac)-Rasagiline can be used for Parkinson's disease research. (Rac)-Rasagiline protects against MPTP (HY-15608)-induced toxicity .
Cat. No.: HY-136804
CAS No.: 1115335-95-9
Target:
Research Areas:
CypD-IN-29 (compound 29) is an inhibitor of the Alzheimer's disease target CypD (KD=88.2 nM). CypD is a mitochondrial-specific cyclophilin that can bind to β-amyloid protein in brain mitochondria and promote the formation of mitochondrial permeability transition pore (mPTP).
Cat. No.: HY-162573
CAS No.: 2969160-15-2
Target:
Research Areas:
Monoamine Oxidase B inhibitor 5 (Compound 16d) is a selective and reversible inhibitor for monoamine oxidase B (hMAO-B) with an IC50 of 67.3 nM and a Ki of 82.5 nM. Monoamine Oxidase B inhibitor 5 exhibits good pharmacokinetic characters and weak toxicity in rats model. Monoamine Oxidase B inhibitor 5 alleviates MPTP-induced (HY-15608) motor impairment in Parkinson’s mouse model. Monoamine Oxidase B inhibitor 5 is blood-brain barrier (BBB) penetrate .
Cat. No.: HY-162760
CAS No.: 2987884-27-3
Target:
Research Areas:
COMT-IN-1 (compound C12), a nitrophenolic analogue, is an orally active dopamine metabolic enzyme catechol-O-methyltransferase (COMT) inhibitor with IC50s of 0.37 μM, 95.58 μM and 58.82 μM for COMT, MAO-A and MAO-B, respectively. COMT-IN-1 exhibits chelation with a variety of metal ions. COMT-IN-1 exhibits good BBB permeability. COMT-IN-1 improves dopamine levels and ameliorates MPTP (HY-15608)-induced Parkinson's disease (PD) symptoms in mice .
Cat. No.: HY-158732
CAS No.: 2286257-25-6
Target:
Research Areas:
MAO-B-IN-33 (compound C3) is a potent, reversible and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.021 μM and 26.805 μM for MAO-B and MAO-A, respectively. The selectivity of MAO-B-IN-33 is attributed to the steric clash arising from the residue differences between Phe208 (MAO-A) and Ile199 (MAO-B). MAO-B-IN-33 inhibits cerebral MAO-B activity and alleviates MPTP (HY-15608)-induced dopaminergic neuronal loss in the mouse. MAO-B-IN-33 has the potential for Parkinson's disease research .
Cat. No.: HY-178352
CAS No.: 3098883-91-8
Research Areas:
MAO-B-IN-49 is a selective and reversible MAO-B inhibitor (IC50 of 1 nM for human MAO-B). MAO-B-IN-49 shows much higher selectivity for MAO-B than for MAO-A (IC50 = 633.9 μM). MAO-B-IN-49 can reduce ROS production induced by Lipopolysaccharides (HY-D1056) (LPS) in HT22 cells. MAO-B-IN-49 demonstrates substantial neuroprotective properties and significantly improves motor dysfunction in MPTP (HY-W114750)-induced mouse models of Parkinson’s disease (PD). MAO-B-IN-49 can be used for the study of PD .
Cat. No.: HY-W587743
CAS No.: 1215711-91-3
Synonyms: AMK hydrochloride
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
N1-Acetyl-5-methoxykynuramine hydrochloride (AMK hydrochloride) is an active metabolite of Melatonin (HY-B0075) with antioxidant activity and blood-brain barrier permeability. N1-Acetyl-5-methoxykynuramine hydrochloride inhibits LPS-induced activation of inducible nitric oxide synthase and COX-2, scavenges ROS, hydroxyl radicals, carbonate radicals and ABTS cation radicals, and protects bovine serum albumin from peroxyl radical-mediated damage. N1-Acetyl-5-methoxykynuramine hydrochloride reduces the increase in cytoplasmic and mitochondrial lipid peroxidation in the substantia nigra and striatum in MPTP (HY-15608)-induced mouse models of Parkinson's disease. N1-Acetyl-5-methoxykynuramine hydrochloride can be used in studies related to Parkinson's disease, metabolism-related diseases and oxidative stress .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
